27-Mar-2026
ACCESS Newswire (Thu, 26-Feb 4:05 PM ET)
Amphastar Announces FDA Approval for Ipratropium Bromide HFA
ACCESS Newswire (Tue, 24-Feb 6:00 AM ET)
ACCESS Newswire (Fri, 20-Feb 6:00 AM ET)
Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference
ACCESS Newswire (Wed, 7-Jan 6:00 AM ET)
FDA Approves Amphastar’s Teriparatide Pen—A Milestone for U.S.-Made Osteoporosis Therapy
Market Chameleon (Mon, 15-Dec 4:05 AM ET)
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
Amphastar Pharmaceuticals trades on the NASDAQ stock market under the symbol AMPH.
As of March 27, 2026, AMPH stock price declined to $19.01 with 323,887 million shares trading.
AMPH has a beta of 0.84, meaning it tends to be less sensitive to market movements. AMPH has a correlation of 0.06 to the broad based SPY ETF.
AMPH has a market cap of $873.55 million. This is considered a Small Cap stock.
Last quarter Amphastar Pharmaceuticals reported $183 million in Revenue and $.73 earnings per share. This fell short of revenue expectation by $-9 million and missed earnings estimates by -$.18.
In the last 3 years, AMPH traded as high as $67.66 and as low as $17.03.
The top ETF exchange traded funds that AMPH belongs to (by Net Assets): IJR, VTI, IWM, AVUV, PJP.
AMPH has underperformed the market in the last year with a return of -33.0%, while the SPY ETF gained +12.8%. In the last 3 month period, AMPH fell short of the market, returning -29.9%, while SPY returned -7.9%. However, in the most recent 2 weeks AMPH has outperformed the stock market by returning +4.6%, while SPY returned -4.5%.
AMPH support price is $18.88 and resistance is $20.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMPH shares will trade within this expected range on the day.